The Global Hemophilia Drugs Market covered the value of US$ 9,875.4 million in the year 2018 and is anticipated to reach US$ 15,830.3 million by 2026. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period.
Request a FREE Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hemophilia-drugs-market-100068
The Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients
North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global hemophilia drugs market.
This is mainly attributable to the rising pool patients suffering from hemophilia across the world. Also, rising initiatives at developing and commercializing new products for the effective treatment of hemophilia is driving this segment’s growth. Following hemophilia, A, hemophilia B drugs are also expected to grow at a considerable rate in the years to come.
Moreover, governments are planning to conduct awareness initiatives to spread knowledge regarding the use of hemophilia treatment and drugs This, in turn, is expected to drive the hemophilia drugs market over the next few years. The genetic evolution is leading to rising incidences of bleeding disorders across the world.
This will further lead to hemophilia drug development in the next few years to come. As per the study conducted by the National Hemophilia Foundation or NHF in 2015, about 1% of the U.S. population is likely to suffer from a disease called von Willebrand, hence rising the need for hemophilia treatment drugs.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hemophilia-drugs-market-100068
Some of the Main Key Players Covered in the Report
- Grifols SA
- CSL Behring
- Octapharma AG
- Pfizer, Inc.
- Bioverativ Inc.
- FERRING LÄKEMEDEL AB
- Aptevo Therapeutics
- Takeda Pharmaceutical Company Limited
- Hoffmann-La Roche Ltd
- Novo Nordisk
Major Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Epidemiology of coagulation factor deficiency & hemophilia
- Recent industry developments such as mergers & acquisitions
- Regulatory scenario in key countries
- New products launch
- Pipeline analysis
- Reimbursement scenario
- Key industry trends
- Global Hemophilia Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings/ Summary
- Market Analysis, Insights and Forecast – By Application
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Market Analysis, Insights and Forecast – By Type
- Recombinant Therapy
- Plasma-derived
- Others
- Market Analysis, Insights and Forecast – By End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Continued…
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245